MOBILion Systems is enabling advancements in disease diagnosis and treatment by commercializing instruments that improve multi-omics disease, drug, and biomarker discovery. Enhancing the study of the complement to genomics provides a better understanding of disease and drug target mechanisms and paves the way for earlier disease detection, more accurate diagnostics, improved treatment options for individual patients, and reduced healthcare costs. MOBILion’s instruments provide unprecedented speed, sensitivity and resolution, allowing rapid detection of clinically relevant molecules such as proteins, peptides, metabolites, lipids, etc., to better predict, diagnose and treat disease. MOBILion’s instruments process population scale samples in days vs. years, and detect low abundance molecules never before seen with existing instrumentation, providing researchers and clinicians with increased confidence in clinical results.
MOBILion Systems is disrupting the separations game, enhancing the way we characterize biotherapeutics and identify biomarkers. Leveraging a 13-meter ion mobility path length to provide deeper level characterization without compromising time, our best-in-class SLIM-based High-Resolution Ion Mobility Mass Spectrometry (HRIM-MS) platforms separate and identify molecules that current platforms fail to detect with faster analysis…
